Transcription Strikes Back: Clinical Utility of Lung Adenocarcinoma Subtypes Available to Purchase

Using transcriptional profiling, three robust subtypes of nonsquamous non–small cell lung cancer were defined, independently of initiating oncogenic driver events. Subtype-specific differential sensitivity to MEK1/2 inhibitors was reported and an interaction between the mucinous subtype, STK11/LKB1 genomic alterations, and inferior clinical outcomes with atezolizumab in the OAK clinical trial was identified.

See related article by Daemen et al., p. 1162